Literature DB >> 11261017

Consumer participation in the development of psychosocial clinical practice guidelines: opinions of women with breast cancer.

N Rankin1, S Newell, R Sanson-Fisher, A Girgis.   

Abstract

Clinical practice guidelines are playing an increasingly important role in defining quality care and consumers have a considerable interest in participating in the development of guidelines. The objective of this study was to explore consumer's perceptions of guideline items relating to psychosocial care of women with breast cancer, developed by Australia's National Health and Medical Research Council National Breast Cancer Centre. Women diagnosed with breast cancer in the previous 2 years (n = 313) received a letter about the study via their radiation oncologist. Consenting women were contacted by the researchers to complete a telephone survey. The survey asked women to rate the importance of draft guidelines items, including discussing prognosis, providing information and choice, doctor-patient communication, preparation for surgery, providing emotional support, providing social support, dealing with practical and cultural issues and continuity of care. One hundred and forty women (45%) completed the survey. The results indicated that at least 50% of respondents rated 28 of the 52 items as 'essential' components, with respondents identifying providing information and choice, and doctor-patient communication as the most important aspects of psychosocial care. The findings suggest the guidelines adequately reflect consumer opinions and identify priority areas for clinicians to address in providing psychosocial support to women with breast cancer.

Entities:  

Mesh:

Year:  2000        PMID: 11261017     DOI: 10.1046/j.1365-2354.2000.00198.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  9 in total

1.  Views of psycho-oncology health professionals on priority psycho-oncology research questions.

Authors:  Nicole M Rankin; Phyllis N Butow; Melanie A Price; Alison Evans
Journal:  Support Care Cancer       Date:  2010-06-10       Impact factor: 3.603

2.  The involvement of gynaecological patients in the development of a clinical guideline for resumption of (work) activities in the Netherlands.

Authors:  Carina A C M Pittens; Antonie Vonk Noordegraaf; Saskia C van Veen; Johannes R Anema; Judith A F Huirne; Jacqueline E W Broerse
Journal:  Health Expect       Date:  2013-08-29       Impact factor: 3.377

Review 3.  What do consumers see as important in the continuity of their care?

Authors:  Megan Barnet; Tim Shaw
Journal:  Support Care Cancer       Date:  2013-07-05       Impact factor: 3.603

4.  A qualitative study of consumer attitudes to sharing psychosocial information within the multidisciplinary cancer care team.

Authors:  Esther Davis; Belinda Thewes; Phyllis Butow; Catherine Mason
Journal:  Support Care Cancer       Date:  2014-01-12       Impact factor: 3.603

5.  Perceived importance of evidence-based psychosocial clinical guidelines for Hong Kong Chinese women with breast cancer: opinions of patients and health care providers.

Authors:  Wendy Wing Tak Lam; Cecilia Fabrizio; Ella Ho; Lillian Chan; Richard Fielding
Journal:  Support Care Cancer       Date:  2008-09-02       Impact factor: 3.603

6.  Doctors' communication of trust, care, and respect in breast cancer: qualitative study.

Authors:  Emma Burkitt Wright; Christopher Holcombe; Peter Salmon
Journal:  BMJ       Date:  2004-03-30

Review 7.  Patient and public involvement in the development of clinical practice guidelines: a scoping review.

Authors:  Elizabeth Ann Bryant; Anna Mae Scott; Hannah Greenwood; Rae Thomas
Journal:  BMJ Open       Date:  2022-09-28       Impact factor: 3.006

8.  Reconsidering patient participation in guideline development.

Authors:  Hester M van de Bovenkamp; Margo J Trappenburg
Journal:  Health Care Anal       Date:  2008-12-20

Review 9.  The patient experience.

Authors:  Nadia Harbeck; Renate Haidinger
Journal:  Breast Cancer Res Treat       Date:  2007-10-03       Impact factor: 4.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.